Kyverna Therapeutics, Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Kyverna reported Q2 2026 cash of $199.4M (relative to $64.5M market cap = 309% coverage), net loss of $38.3M ($0.63/share), and R&D expenses of $24.8M. FDA granted RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis based on Stanford/UCSF investigator-initiated trial data. Rolling BLA submission for stiff person syndrome initiated with CMC module submitted; company targets Q4 2026 completion and potential 2027 commercial launch. Phase 3 gMG enrollment expected complete mid-2027; KYSA-8 12-month data due Q3 2026. Operating runway extended into 2028.
Why this rating
RMAT designation expands pipeline optionality and accelerates regulatory path; on-track SPS BLA is material near-term catalyst. However, biotech early-stage; approval not guaranteed. Relative to $64.5M market cap, $199.4M cash is substantial runway but burn rate ($39.6M/quarter) means ~5 quarters remaining—approval timeline critical.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.